Comparing metagenomic profiles of the skin microbiome in immunosuppressed patients and those at high and low risk for cutaneous squamous cell carcinoma (SCC) revealed distinct expansions in fungal and ...
Libtayo is approved for adjuvant treatment in high-risk CSCC patients post-surgery and radiation, showing significant disease-free survival benefits in the C-POST trial. The C-POST trial excluded ...
Patients who have cutaneous squamous-cell carcinoma with high-risk features are at risk for recurrence after definitive local therapy. The benefit of systemic adjuvant therapy options has not been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results